Snapshot from Jul 07, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Catalyst Pharmaceuticals

Tracked across 3 events · 18 articles · First seen Apr 23, 2026 · Last active Jul 01, 2026

Sentiment
20
Attention
4
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 60
Tech
Impact: Catalyst Pharmaceuticals conducted the Phase 1 study of AGAMREE and holds commercialization rights in North America. Positive results support its potential to expand the drug's use beyond Duchenne muscular dystrophy, increasing its market potential.
Jul 01, 2026 · 6 articles
2 0
Business
Impact: Santhera Pharmaceuticals has partnered with Catalyst Pharmaceuticals for the North American rights to AGAMREE.
Apr 23, 2026 · 6 articles
2 0
Business
Impact: Catalyst Pharmaceuticals holds the North American rights to AGAMREE, licensed from Santhera Pharmaceuticals.
Apr 30, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Catalyst Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.